Breaking News

Momenta Acquires Antibody Program from AnaptysBio

Therapeutic antibodies target autoimmune disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Momenta Pharmaceuticals, Inc. has exercised its option to acquire a novel antibody program from AnaptysBio, gaining worldwide rights to therapeutic antibodies against a target selected based on the anti-inflammatory effects of IVIg.    “We are pleased to have successfully achieved this milestone with Momenta and look forward to their advancement of the antibodies generated by AnaptysBio’s SHM-XEL platform. This program synergized AnaptysBio’s leadership in antibody development ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters